Lundbeck Serlect NDA Revival Is One Project For CEO-Elect Braestrup
Executive Summary
Lundbeck CEO-elect Claus Braestrup will oversee the company's renewed attempt to launch the antipsychotic Serlect (sertindole) in the U.S. when he assumes leadership of the Danish company in November